| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventricular Function, Left | 52 | 2025 | 268 | 6.360 |
Why?
|
| Ventricular Dysfunction, Left | 36 | 2025 | 164 | 6.240 |
Why?
|
| Echocardiography | 75 | 2025 | 498 | 6.200 |
Why?
|
| Stroke Volume | 45 | 2025 | 328 | 4.040 |
Why?
|
| Hypertension | 42 | 2024 | 590 | 3.850 |
Why?
|
| Echocardiography, Doppler | 41 | 2024 | 133 | 3.800 |
Why?
|
| Hypertrophy, Left Ventricular | 37 | 2023 | 123 | 3.650 |
Why?
|
| Heart Ventricles | 35 | 2025 | 261 | 3.650 |
Why?
|
| Diastole | 28 | 2024 | 92 | 3.260 |
Why?
|
| Aortic Valve Stenosis | 20 | 2021 | 186 | 3.120 |
Why?
|
| Heart Failure | 41 | 2024 | 899 | 3.060 |
Why?
|
| Ventricular Remodeling | 13 | 2021 | 83 | 2.730 |
Why?
|
| Takotsubo Cardiomyopathy | 8 | 2023 | 65 | 2.640 |
Why?
|
| Heart Valve Diseases | 9 | 2024 | 93 | 1.960 |
Why?
|
| Systole | 26 | 2021 | 109 | 1.930 |
Why?
|
| Cardiomyopathies | 7 | 2024 | 123 | 1.640 |
Why?
|
| Myocardial Contraction | 19 | 2012 | 88 | 1.580 |
Why?
|
| Aortic Valve | 10 | 2021 | 187 | 1.500 |
Why?
|
| Ventricular Pressure | 9 | 2024 | 30 | 1.460 |
Why?
|
| Echocardiography, Three-Dimensional | 5 | 2024 | 44 | 1.410 |
Why?
|
| Humans | 187 | 2025 | 62541 | 1.410 |
Why?
|
| Aortic Valve Insufficiency | 10 | 2020 | 42 | 1.280 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2023 | 108 | 1.250 |
Why?
|
| Heart Atria | 11 | 2023 | 138 | 1.240 |
Why?
|
| Mitral Valve Insufficiency | 12 | 2024 | 81 | 1.190 |
Why?
|
| Antihypertensive Agents | 13 | 2021 | 171 | 1.110 |
Why?
|
| Aged | 91 | 2024 | 14206 | 1.070 |
Why?
|
| Female | 110 | 2025 | 32398 | 1.020 |
Why?
|
| Heart Diseases | 8 | 2019 | 215 | 0.960 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 24 | 0.910 |
Why?
|
| Atrial Function, Left | 6 | 2024 | 32 | 0.900 |
Why?
|
| Heart | 7 | 2019 | 281 | 0.880 |
Why?
|
| Cardiac Catheterization | 13 | 2024 | 278 | 0.860 |
Why?
|
| Male | 103 | 2024 | 29387 | 0.850 |
Why?
|
| Aged, 80 and over | 32 | 2021 | 5389 | 0.850 |
Why?
|
| Diagnostic Imaging | 5 | 2013 | 261 | 0.820 |
Why?
|
| Predictive Value of Tests | 13 | 2024 | 1076 | 0.790 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 831 | 0.760 |
Why?
|
| Obesity | 7 | 2019 | 1228 | 0.760 |
Why?
|
| Hypertension, Pulmonary | 3 | 2021 | 95 | 0.750 |
Why?
|
| Middle Aged | 76 | 2024 | 17298 | 0.750 |
Why?
|
| Atrial Fibrillation | 8 | 2020 | 831 | 0.750 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2016 | 57 | 0.700 |
Why?
|
| Myocardium | 8 | 2017 | 274 | 0.690 |
Why?
|
| Pheochromocytoma | 1 | 2020 | 26 | 0.690 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2020 | 43 | 0.680 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2020 | 6 | 0.680 |
Why?
|
| Myocarditis | 1 | 2021 | 67 | 0.680 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 9 | 0.650 |
Why?
|
| Heart Valves | 3 | 2018 | 25 | 0.630 |
Why?
|
| Mitral Valve | 11 | 2024 | 116 | 0.630 |
Why?
|
| Atrial Pressure | 1 | 2019 | 5 | 0.620 |
Why?
|
| Retrospective Studies | 21 | 2024 | 6489 | 0.610 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 107 | 0.610 |
Why?
|
| Renin-Angiotensin System | 3 | 2011 | 22 | 0.580 |
Why?
|
| Dilatation | 2 | 2016 | 32 | 0.550 |
Why?
|
| Blood Pressure | 15 | 2021 | 513 | 0.540 |
Why?
|
| Calcium | 1 | 2020 | 571 | 0.540 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2025 | 763 | 0.530 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 1637 | 0.520 |
Why?
|
| Follow-Up Studies | 19 | 2021 | 2441 | 0.520 |
Why?
|
| Hyperaldosteronism | 1 | 2016 | 5 | 0.520 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 725 | 0.520 |
Why?
|
| Losartan | 7 | 2014 | 19 | 0.520 |
Why?
|
| Mitoxantrone | 1 | 2016 | 16 | 0.510 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2025 | 2142 | 0.490 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 253 | 0.490 |
Why?
|
| Algorithms | 5 | 2017 | 1003 | 0.480 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 143 | 0.460 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2024 | 65 | 0.460 |
Why?
|
| Treatment Outcome | 16 | 2021 | 5556 | 0.450 |
Why?
|
| Prevalence | 15 | 2021 | 1343 | 0.440 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 138 | 0.430 |
Why?
|
| Myocardial Infarction | 12 | 2021 | 909 | 0.430 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2012 | 178 | 0.420 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 189 | 0.420 |
Why?
|
| Risk Factors | 24 | 2021 | 5289 | 0.420 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2024 | 33 | 0.400 |
Why?
|
| Aging | 4 | 2011 | 738 | 0.400 |
Why?
|
| Heart Failure, Diastolic | 2 | 2010 | 9 | 0.400 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2013 | 111 | 0.380 |
Why?
|
| Heart Valve Prosthesis | 7 | 2021 | 107 | 0.380 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2018 | 168 | 0.370 |
Why?
|
| Gated Blood-Pool Imaging | 2 | 2009 | 11 | 0.370 |
Why?
|
| Electrocardiography | 15 | 2024 | 549 | 0.350 |
Why?
|
| Aorta | 2 | 2021 | 112 | 0.350 |
Why?
|
| Cardiology | 4 | 2022 | 167 | 0.340 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2010 | 33 | 0.340 |
Why?
|
| Incidence | 11 | 2021 | 1359 | 0.320 |
Why?
|
| Survival Rate | 8 | 2018 | 838 | 0.310 |
Why?
|
| Electric Countershock | 2 | 2012 | 101 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 667 | 0.300 |
Why?
|
| Diagnosis, Differential | 9 | 2013 | 963 | 0.300 |
Why?
|
| Adult | 31 | 2025 | 16575 | 0.300 |
Why?
|
| Prognosis | 18 | 2023 | 1717 | 0.300 |
Why?
|
| Organ Size | 6 | 2014 | 171 | 0.290 |
Why?
|
| Age Factors | 10 | 2021 | 1553 | 0.290 |
Why?
|
| Cardiac Volume | 1 | 2007 | 7 | 0.290 |
Why?
|
| Phenotype | 3 | 2025 | 1190 | 0.290 |
Why?
|
| Conscious Sedation | 2 | 2004 | 39 | 0.280 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2025 | 360 | 0.280 |
Why?
|
| Pulmonary Artery | 3 | 2021 | 93 | 0.270 |
Why?
|
| Time Factors | 13 | 2021 | 3737 | 0.260 |
Why?
|
| Sensitivity and Specificity | 8 | 2016 | 1139 | 0.260 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2017 | 49 | 0.260 |
Why?
|
| Catheter Ablation | 3 | 2024 | 153 | 0.250 |
Why?
|
| Calcinosis | 3 | 2024 | 83 | 0.250 |
Why?
|
| Disease Progression | 9 | 2013 | 1159 | 0.240 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 207 | 0.240 |
Why?
|
| Geriatric Assessment | 2 | 2004 | 163 | 0.240 |
Why?
|
| Cardiomegaly | 4 | 2016 | 34 | 0.240 |
Why?
|
| Societies, Medical | 5 | 2018 | 362 | 0.230 |
Why?
|
| United States | 15 | 2025 | 7702 | 0.230 |
Why?
|
| Stress, Physiological | 2 | 2009 | 193 | 0.230 |
Why?
|
| Dexfenfluramine | 2 | 2002 | 4 | 0.230 |
Why?
|
| Blood Flow Velocity | 5 | 2009 | 72 | 0.230 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 21 | 0.220 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2004 | 104 | 0.220 |
Why?
|
| Endocardium | 4 | 2010 | 13 | 0.220 |
Why?
|
| Pericardium | 1 | 2023 | 34 | 0.210 |
Why?
|
| Heart Function Tests | 4 | 2005 | 15 | 0.210 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 16 | 0.200 |
Why?
|
| Prospective Studies | 14 | 2016 | 3248 | 0.200 |
Why?
|
| Stress, Psychological | 2 | 2009 | 469 | 0.200 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1538 | 0.190 |
Why?
|
| Mitral Valve Annuloplasty | 2 | 2020 | 19 | 0.190 |
Why?
|
| Tachycardia, Ventricular | 1 | 2024 | 129 | 0.190 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2002 | 13 | 0.190 |
Why?
|
| Aortic Aneurysm | 2 | 2020 | 84 | 0.190 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2021 | 9 | 0.190 |
Why?
|
| Mitral Valve Prolapse | 1 | 2021 | 11 | 0.190 |
Why?
|
| Heart Rate | 7 | 2010 | 319 | 0.190 |
Why?
|
| Vasodilator Agents | 4 | 2004 | 67 | 0.190 |
Why?
|
| Appetite Depressants | 2 | 1998 | 5 | 0.190 |
Why?
|
| Case-Control Studies | 8 | 2016 | 1107 | 0.180 |
Why?
|
| Obstetric Labor Complications | 1 | 2021 | 24 | 0.180 |
Why?
|
| Sex Factors | 6 | 2021 | 969 | 0.180 |
Why?
|
| Nephritis, Hereditary | 1 | 2020 | 2 | 0.180 |
Why?
|
| Endocarditis | 1 | 2021 | 28 | 0.180 |
Why?
|
| Adrenergic Agents | 1 | 2020 | 15 | 0.180 |
Why?
|
| Advisory Committees | 3 | 2018 | 112 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2021 | 724 | 0.170 |
Why?
|
| Atrial Remodeling | 1 | 2020 | 17 | 0.170 |
Why?
|
| Massachusetts | 7 | 2016 | 2061 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2013 | 411 | 0.170 |
Why?
|
| Contrast Media | 4 | 2010 | 421 | 0.170 |
Why?
|
| Comorbidity | 5 | 2017 | 1117 | 0.170 |
Why?
|
| Hospitalization | 5 | 2021 | 1338 | 0.160 |
Why?
|
| Heart Failure, Systolic | 2 | 2010 | 16 | 0.160 |
Why?
|
| Ventricular Dysfunction | 3 | 2006 | 13 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2021 | 151 | 0.160 |
Why?
|
| Coronary Angiography | 4 | 2013 | 200 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 353 | 0.150 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1260 | 0.150 |
Why?
|
| Registries | 3 | 2021 | 870 | 0.150 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2024 | 99 | 0.150 |
Why?
|
| Hemodynamics | 11 | 2015 | 242 | 0.140 |
Why?
|
| Pacemaker, Artificial | 3 | 2013 | 49 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 452 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2018 | 70 | 0.140 |
Why?
|
| Coronary Vessels | 2 | 2013 | 118 | 0.140 |
Why?
|
| Valine | 2 | 2007 | 31 | 0.130 |
Why?
|
| Tetrazoles | 2 | 2007 | 22 | 0.130 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2007 | 25 | 0.130 |
Why?
|
| Gravidity | 1 | 2016 | 12 | 0.130 |
Why?
|
| Reproductive History | 1 | 2016 | 17 | 0.130 |
Why?
|
| Menstruation Disturbances | 1 | 2016 | 18 | 0.130 |
Why?
|
| Consensus | 2 | 2015 | 224 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 688 | 0.130 |
Why?
|
| Heart Defects, Congenital | 2 | 2016 | 100 | 0.130 |
Why?
|
| Sleep | 1 | 2019 | 225 | 0.130 |
Why?
|
| Aldosterone | 1 | 2016 | 18 | 0.130 |
Why?
|
| Analysis of Variance | 5 | 2014 | 608 | 0.130 |
Why?
|
| Personality | 1 | 2016 | 28 | 0.130 |
Why?
|
| Mathematics | 1 | 2016 | 34 | 0.130 |
Why?
|
| Linear Models | 3 | 2016 | 408 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2016 | 80 | 0.130 |
Why?
|
| Reference Values | 4 | 2009 | 335 | 0.130 |
Why?
|
| Causality | 1 | 2016 | 58 | 0.130 |
Why?
|
| Ventricular Function | 3 | 2010 | 22 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 1997 | 190 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 169 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 1529 | 0.120 |
Why?
|
| Stroke | 5 | 2021 | 1184 | 0.120 |
Why?
|
| Coronary Circulation | 2 | 1992 | 51 | 0.120 |
Why?
|
| Observer Variation | 3 | 2019 | 211 | 0.120 |
Why?
|
| Coronary Artery Bypass | 2 | 2004 | 297 | 0.120 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 414 | 0.120 |
Why?
|
| Europe | 4 | 2015 | 193 | 0.120 |
Why?
|
| Sleep Stages | 1 | 1994 | 16 | 0.110 |
Why?
|
| Mediastinal Diseases | 1 | 1994 | 15 | 0.110 |
Why?
|
| Confusion | 1 | 1994 | 17 | 0.110 |
Why?
|
| Coronary Disease | 4 | 2003 | 246 | 0.110 |
Why?
|
| Exercise Test | 5 | 2004 | 249 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 490 | 0.110 |
Why?
|
| HIV Infections | 1 | 2021 | 962 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 1994 | 203 | 0.110 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2021 | 149 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 675 | 0.110 |
Why?
|
| Movement Disorders | 1 | 2013 | 23 | 0.110 |
Why?
|
| Patient Selection | 2 | 2007 | 481 | 0.100 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hepatic Veins | 1 | 2013 | 13 | 0.100 |
Why?
|
| Anxiety | 1 | 2016 | 421 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 928 | 0.100 |
Why?
|
| Elastic Modulus | 1 | 2012 | 38 | 0.100 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2012 | 16 | 0.100 |
Why?
|
| Syndrome | 4 | 2006 | 179 | 0.100 |
Why?
|
| Reference Standards | 3 | 2018 | 73 | 0.090 |
Why?
|
| Coronary Artery Disease | 3 | 2013 | 308 | 0.090 |
Why?
|
| Procollagen | 1 | 2011 | 10 | 0.090 |
Why?
|
| Aortography | 1 | 1992 | 57 | 0.090 |
Why?
|
| Scotland | 1 | 2011 | 10 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2011 | 41 | 0.090 |
Why?
|
| Morbidity | 3 | 2017 | 113 | 0.090 |
Why?
|
| Pregnancy | 3 | 2024 | 2315 | 0.090 |
Why?
|
| Torsades de Pointes | 1 | 2010 | 6 | 0.090 |
Why?
|
| Chronic Disease | 5 | 2005 | 748 | 0.090 |
Why?
|
| Serotonin Syndrome | 1 | 2011 | 10 | 0.090 |
Why?
|
| Collagen | 1 | 2011 | 127 | 0.090 |
Why?
|
| Long QT Syndrome | 1 | 2010 | 31 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 660 | 0.090 |
Why?
|
| Logistic Models | 4 | 2021 | 1273 | 0.090 |
Why?
|
| Area Under Curve | 2 | 2024 | 146 | 0.090 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 172 | 0.090 |
Why?
|
| Cardiotonic Agents | 2 | 2009 | 53 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1247 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2010 | 63 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 1584 | 0.080 |
Why?
|
| Biomarkers | 5 | 2020 | 1379 | 0.080 |
Why?
|
| Angiocardiography | 1 | 2009 | 6 | 0.080 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1989 | 62 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2006 | 212 | 0.080 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2008 | 27 | 0.080 |
Why?
|
| Body Surface Area | 1 | 2009 | 11 | 0.080 |
Why?
|
| Body Size | 1 | 2009 | 24 | 0.080 |
Why?
|
| Depression | 1 | 2016 | 883 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 461 | 0.080 |
Why?
|
| Fluorocarbons | 2 | 2000 | 38 | 0.080 |
Why?
|
| Kidney | 1 | 2011 | 444 | 0.080 |
Why?
|
| Injections, Intravenous | 3 | 2004 | 156 | 0.080 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 128 | 0.080 |
Why?
|
| Fenfluramine | 2 | 1998 | 4 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2010 | 2033 | 0.070 |
Why?
|
| Angina Pectoris | 3 | 2021 | 38 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1065 | 0.070 |
Why?
|
| Regression Analysis | 5 | 2006 | 497 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 203 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 573 | 0.070 |
Why?
|
| Biomechanical Phenomena | 2 | 2024 | 269 | 0.070 |
Why?
|
| Inpatients | 1 | 2010 | 301 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2013 | 738 | 0.070 |
Why?
|
| Animals | 7 | 2015 | 20570 | 0.060 |
Why?
|
| Catecholamines | 1 | 2006 | 31 | 0.060 |
Why?
|
| Dipyridamole | 2 | 1998 | 17 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 2530 | 0.060 |
Why?
|
| Myocardial Ischemia | 3 | 2003 | 115 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2020 | 575 | 0.060 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 535 | 0.060 |
Why?
|
| Ultrasonography | 4 | 2009 | 474 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 768 | 0.060 |
Why?
|
| Midazolam | 1 | 2004 | 12 | 0.060 |
Why?
|
| Recurrence | 3 | 2016 | 630 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2004 | 37 | 0.060 |
Why?
|
| American Heart Association | 1 | 2025 | 126 | 0.060 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 26 | 0.060 |
Why?
|
| Pressure | 1 | 2004 | 77 | 0.060 |
Why?
|
| Peripartum Period | 1 | 2024 | 21 | 0.060 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2004 | 5 | 0.060 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2004 | 25 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2006 | 210 | 0.050 |
Why?
|
| Fentanyl | 1 | 2004 | 75 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1180 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2003 | 4 | 0.050 |
Why?
|
| Cardiovascular Agents | 1 | 2004 | 103 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2531 | 0.050 |
Why?
|
| Research Design | 1 | 2006 | 572 | 0.050 |
Why?
|
| Viridans Streptococci | 1 | 2002 | 5 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1999 | 104 | 0.050 |
Why?
|
| Patient Discharge | 2 | 2016 | 505 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2003 | 103 | 0.050 |
Why?
|
| Atenolol | 2 | 2014 | 12 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2002 | 6 | 0.050 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 79 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2002 | 26 | 0.050 |
Why?
|
| Abscess | 1 | 2002 | 78 | 0.050 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 2 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 727 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 56 | 0.040 |
Why?
|
| Heart Injuries | 2 | 1992 | 18 | 0.040 |
Why?
|
| HIV | 1 | 2021 | 70 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 101 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2022 | 196 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2020 | 21 | 0.040 |
Why?
|
| Tubulin | 1 | 2001 | 73 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2020 | 126 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 30 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2012 | 620 | 0.040 |
Why?
|
| Curriculum | 2 | 2022 | 585 | 0.040 |
Why?
|
| Rats | 4 | 2012 | 1977 | 0.040 |
Why?
|
| Syncope | 2 | 1998 | 42 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2021 | 166 | 0.040 |
Why?
|
| Italy | 2 | 2015 | 66 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 36 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 20 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 1998 | 21 | 0.040 |
Why?
|
| Cause of Death | 2 | 2014 | 220 | 0.040 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 17 | 0.040 |
Why?
|
| Phentermine | 1 | 1998 | 2 | 0.040 |
Why?
|
| Dopamine Agents | 1 | 1998 | 11 | 0.040 |
Why?
|
| Adenosine | 1 | 1998 | 78 | 0.040 |
Why?
|
| Serotonin Agents | 1 | 1998 | 10 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 1998 | 76 | 0.040 |
Why?
|
| Atrioventricular Node | 1 | 1997 | 9 | 0.040 |
Why?
|
| Cardiac Output | 1 | 1997 | 28 | 0.040 |
Why?
|
| Endocarditis, Bacterial | 1 | 1998 | 36 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 427 | 0.030 |
Why?
|
| Valsartan | 2 | 2007 | 12 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2013 | 78 | 0.030 |
Why?
|
| Postoperative Period | 2 | 1998 | 137 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 2 | 2000 | 96 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 2016 | 23 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 463 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 712 | 0.030 |
Why?
|
| Connecticut | 1 | 2016 | 88 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2016 | 101 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2016 | 46 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2016 | 67 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 416 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 277 | 0.030 |
Why?
|
| New England | 1 | 2016 | 272 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 1996 | 42 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 850 | 0.030 |
Why?
|
| Postmenopause | 1 | 2016 | 236 | 0.030 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 1994 | 3 | 0.030 |
Why?
|
| Sinus of Valsalva | 1 | 1994 | 7 | 0.030 |
Why?
|
| Industry | 1 | 2014 | 61 | 0.030 |
Why?
|
| Specialization | 1 | 1995 | 81 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2016 | 148 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1995 | 185 | 0.030 |
Why?
|
| Death | 1 | 2014 | 29 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 1994 | 115 | 0.030 |
Why?
|
| Motion Pictures | 2 | 1990 | 11 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2013 | 71 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 75 | 0.030 |
Why?
|
| Education, Medical | 1 | 1995 | 182 | 0.030 |
Why?
|
| Hematocrit | 1 | 1992 | 32 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 2641 | 0.020 |
Why?
|
| Video Recording | 2 | 2005 | 133 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 65 | 0.020 |
Why?
|
| Cineangiography | 1 | 1992 | 2 | 0.020 |
Why?
|
| Acute Disease | 2 | 2010 | 670 | 0.020 |
Why?
|
| Arteries | 1 | 2012 | 81 | 0.020 |
Why?
|
| Medicare | 2 | 2007 | 614 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1992 | 65 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2011 | 38 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 1992 | 105 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4612 | 0.020 |
Why?
|
| Thrombosis | 1 | 1992 | 199 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2010 | 40 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 861 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 373 | 0.020 |
Why?
|
| Vascular Patency | 1 | 1989 | 139 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 112 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 282 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 159 | 0.020 |
Why?
|
| Creatine Kinase | 2 | 2003 | 42 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 1988 | 12 | 0.020 |
Why?
|
| Single-Blind Method | 2 | 1998 | 142 | 0.020 |
Why?
|
| Isoenzymes | 2 | 2003 | 140 | 0.020 |
Why?
|
| Exercise | 1 | 2015 | 936 | 0.020 |
Why?
|
| Mass Screening | 2 | 2003 | 686 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1992 | 866 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 101 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1987 | 293 | 0.020 |
Why?
|
| Health Resources | 1 | 2007 | 91 | 0.020 |
Why?
|
| Physical Exertion | 2 | 1998 | 79 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 38 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 983 | 0.010 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 32 | 0.010 |
Why?
|
| Child | 2 | 2003 | 4430 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2003 | 34 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2003 | 25 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 9 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2003 | 23 | 0.010 |
Why?
|
| Troponin I | 1 | 2003 | 36 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2003 | 84 | 0.010 |
Why?
|
| Homosexuality | 1 | 1982 | 6 | 0.010 |
Why?
|
| Immunoglobulins | 2 | 1998 | 77 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1982 | 19 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 143 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2003 | 153 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2003 | 175 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1982 | 114 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1992 | 122 | 0.010 |
Why?
|
| Manometry | 1 | 2001 | 27 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 458 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 197 | 0.010 |
Why?
|
| Densitometry | 1 | 2000 | 12 | 0.010 |
Why?
|
| Critical Illness | 1 | 2003 | 321 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 144 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 1338 | 0.010 |
Why?
|
| Survival | 1 | 1998 | 12 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 11 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 888 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 1592 | 0.010 |
Why?
|
| Perfusion | 1 | 1998 | 73 | 0.010 |
Why?
|
| Coronary Care Units | 1 | 1998 | 4 | 0.010 |
Why?
|
| Health Status | 1 | 2001 | 433 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1928 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1998 | 34 | 0.010 |
Why?
|
| Methoxamine | 1 | 1997 | 1 | 0.010 |
Why?
|
| Sick Sinus Syndrome | 1 | 1997 | 5 | 0.010 |
Why?
|
| Atrial Function | 1 | 1997 | 5 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1997 | 36 | 0.010 |
Why?
|
| Heart Block | 1 | 1997 | 22 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1997 | 37 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1998 | 194 | 0.010 |
Why?
|
| Body Weight | 1 | 1998 | 377 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1997 | 70 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 230 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 11 | 0.010 |
Why?
|
| Mechanoreceptors | 1 | 1996 | 13 | 0.010 |
Why?
|
| Rome | 1 | 1995 | 2 | 0.010 |
Why?
|
| Fosinopril | 1 | 1995 | 2 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1995 | 185 | 0.010 |
Why?
|
| Emulsions | 1 | 1998 | 472 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2173 | 0.010 |
Why?
|
| Lung | 1 | 1998 | 939 | 0.010 |
Why?
|
| Educational Measurement | 1 | 1995 | 216 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 6150 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 1992 | 41 | 0.010 |
Why?
|
| Thoracic Injuries | 1 | 1992 | 46 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1991 | 9 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1992 | 308 | 0.010 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1992 | 107 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 1995 | 864 | 0.010 |
Why?
|
| Wounds, Stab | 1 | 1989 | 13 | 0.010 |
Why?
|
| Heart Septum | 1 | 1989 | 56 | 0.000 |
Why?
|
| Administration, Sublingual | 1 | 1988 | 3 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1988 | 173 | 0.000 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1987 | 20 | 0.000 |
Why?
|
| Sulfamethizole | 1 | 1982 | 2 | 0.000 |
Why?
|
| Candidiasis, Oral | 1 | 1982 | 6 | 0.000 |
Why?
|
| Trimethoprim | 1 | 1982 | 7 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1982 | 152 | 0.000 |
Why?
|
| California | 1 | 1982 | 174 | 0.000 |
Why?
|
| Cytomegalovirus Infections | 1 | 1982 | 66 | 0.000 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1982 | 96 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1982 | 1004 | 0.000 |
Why?
|